CN119365205A - 副干酪乳杆菌细菌菌株治疗新生儿的用途 - Google Patents

副干酪乳杆菌细菌菌株治疗新生儿的用途 Download PDF

Info

Publication number
CN119365205A
CN119365205A CN202280049761.9A CN202280049761A CN119365205A CN 119365205 A CN119365205 A CN 119365205A CN 202280049761 A CN202280049761 A CN 202280049761A CN 119365205 A CN119365205 A CN 119365205A
Authority
CN
China
Prior art keywords
bacterial strain
group
lactobacillus paracasei
ibs
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280049761.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·比菲
W·菲奥里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Publication of CN119365205A publication Critical patent/CN119365205A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280049761.9A 2021-07-15 2022-07-15 副干酪乳杆菌细菌菌株治疗新生儿的用途 Pending CN119365205A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102021000018740 2021-07-15
IT102021000018740A IT202100018740A1 (it) 2021-07-15 2021-07-15 Uso di ceppi di batteri Lactobacillus paracasei nel trattamento di neonati
PCT/IB2022/056538 WO2023286027A1 (en) 2021-07-15 2022-07-15 Use of lactobacillus paracasei bacterial strains in the treatment of newborns

Publications (1)

Publication Number Publication Date
CN119365205A true CN119365205A (zh) 2025-01-24

Family

ID=78212428

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280049761.9A Pending CN119365205A (zh) 2021-07-15 2022-07-15 副干酪乳杆菌细菌菌株治疗新生儿的用途

Country Status (11)

Country Link
US (1) US20240350567A1 (https=)
EP (1) EP4370142A1 (https=)
JP (1) JP2024525794A (https=)
KR (1) KR20240038015A (https=)
CN (1) CN119365205A (https=)
AU (1) AU2022312760A1 (https=)
CA (1) CA3222905A1 (https=)
IL (1) IL309883A (https=)
IT (1) IT202100018740A1 (https=)
MX (1) MX2024000520A (https=)
WO (1) WO2023286027A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118813489A (zh) * 2024-08-29 2024-10-22 北京科拓恒通生物技术股份有限公司 一种用于缓解便秘和腹泻的益生菌后生元和制备方法及其用途
CN120361059A (zh) * 2025-06-30 2025-07-25 天津创源生物技术有限公司 一种副干酪乳酪杆菌iob413后生元在胃食管反流上的应用
CN121533530A (zh) * 2026-01-19 2026-02-17 内蒙古农业大学 一种副干酪乳酪杆菌-复合益生元复配制剂、制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
IT201900000801A1 (it) * 2019-01-18 2020-07-18 Proge Farm Srl Composizione comprendente batteri probiotici non vitali e suo uso in terapia
IT201900016865A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
IT201900016811A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Ceppi batterici, loro composizioni e loro uso per il trattamento di disturbi gastrointestinali
IT201900020422A1 (it) * 2019-11-05 2021-05-05 Sofar Spa Composizioni comprendenti ceppi di batteri per uso per aumentare la biodisponibilità degli amminoacidi derivanti da proteine
IT202000012448A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
IT202100008300A1 (it) * 2021-04-01 2022-10-01 Bll Invest S R L Ceppi di batteri inattivati, quali batteri vitali ma non coltivabili, loro composizioni e loro uso

Also Published As

Publication number Publication date
AU2022312760A1 (en) 2024-02-22
US20240350567A1 (en) 2024-10-24
WO2023286027A1 (en) 2023-01-19
KR20240038015A (ko) 2024-03-22
IL309883A (en) 2024-03-01
CA3222905A1 (en) 2023-01-19
IT202100018740A1 (it) 2023-01-15
JP2024525794A (ja) 2024-07-12
MX2024000520A (es) 2024-01-31
EP4370142A1 (en) 2024-05-22

Similar Documents

Publication Publication Date Title
Martín et al. Faecalibacterium: a bacterial genus with promising human health applications
He et al. Lactobacillus reuteri reduces the severity of experimental autoimmune encephalomyelitis in mice by modulating gut microbiota
Yan et al. A ropy exopolysaccharide producing strain Bifidobacterium longum subsp. longum YS108R alleviates DSS-induced colitis by maintenance of the mucosal barrier and gut microbiota modulation
Wang et al. Bifidobacteria exert species-specific effects on constipation in BALB/c mice
Li et al. Early development of the gut microbiome and immune-mediated childhood disorders
EP3223838B1 (en) Gold kiwifruit compositions and methods of preparation and use therefor
US20230048705A1 (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
CN119365205A (zh) 副干酪乳杆菌细菌菌株治疗新生儿的用途
Zhang et al. Lactiplantibacillus plantarum ST-III-fermented milk improves autistic-like behaviors in valproic acid-induced autism spectrum disorder mice by altering gut microbiota
JP2024518084A (ja) 疾患を治療するための組成物及び方法
EP4251183A1 (en) Methods of preventing, delaying or ameliorating atopic diseases
CN114615971A (zh) 包含细菌菌株的组合物
JPWO2023286027A5 (https=)
EA053058B1 (ru) Применение бактериальных штаммов lactobacillus paracasei для лечения новорожденных
Archer Gut bacterial dysbiosis and its clinical implications
Sobouti et al. Use of probiotic for the treatment of acute rotavirus diarrhea in children: A randomized single-blind controlled trial
DK202430232A1 (en) Nutritional composition comprising bifidobacterium bifidum r0071 and human milk oligosaccharides
Bhardwaj Gut Flora: In the Treatment of Disease
Pino et al. Lactobacillus rhamnosus GG supplementation in Systemic Nickel allergy Syndrome patients
Ba A study on the effect of delivery vehicles on the efficacy of Bifidobacterium animalis subsp. lactis BB-12 in humans
HK40009064B (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
HK40009064A (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
EA040422B1 (ru) Применение пробиотиков в лечении и/или профилактике атопического дерматита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination